Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from ...
The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The second executive at a drugmaker said his company was "stockpiling" in the United States, the pharma industry's ...
The pharmaceutical industry avoided immediate tariffs under President Donald Trump’s latest trade actions, though future levies remain a possibility. Here are four things to know: ...
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.
Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback